NO326968B1 - PAF-AH-polypeptidfragment, isolert polynukleotid, DNA-vektor, vertscelle, fremgangsmate for fremstilling av et PAF-AH-polypeptidfragment, en variant eller et variant-fragment av plasma-PAF-AH, PAF-AH-polypeptidfragment, variant eller variantfragment, farmasoytisk preparat, anvendelse av PAF-AH-fragmentet, varianten eller variantfragmentet for fremstilling av et medikament for behandling av et pattedyr. - Google Patents

Info

Publication number

NO326968B1

NO326968B1 NO19991717A NO991717A NO326968B1 NO 326968 B1 NO326968 B1 NO 326968B1 NO 19991717 A NO19991717 A NO 19991717A NO 991717 A NO991717 A NO 991717A NO 326968 B1 NO326968 B1 NO 326968B1

Authority

NO

Norway

Prior art keywords

paf

fragment

variant

activity

rph

Prior art date

1997-08-13

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 title claims description 70
• 238000000034 method Methods 0.000 title claims description 47
• 238000002360 preparation method Methods 0.000 title claims description 31
• 108090000765 processed proteins & peptides Proteins 0.000 title claims description 31
• 229920001184 polypeptide Polymers 0.000 title claims description 28
• 102000004196 processed proteins & peptides Human genes 0.000 title claims description 28
• 239000013598 vector Substances 0.000 title claims description 13
• 108091033319 polynucleotide Proteins 0.000 title claims description 10
• 102000040430 polynucleotide Human genes 0.000 title claims description 10
• 239000002157 polynucleotide Substances 0.000 title claims description 10
• 241000124008 Mammalia Species 0.000 title claims description 7
• 239000003814 drug Substances 0.000 title claims description 6
• 230000008569 process Effects 0.000 title description 5
• 239000008194 pharmaceutical composition Substances 0.000 title description 2
• 230000000694 effects Effects 0.000 claims description 164
• 210000004027 cell Anatomy 0.000 claims description 110
• 230000014509 gene expression Effects 0.000 claims description 58
• 238000011282 treatment Methods 0.000 claims description 44
• 206010051606 Necrotising colitis Diseases 0.000 claims description 41
• 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 41
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 41
• 150000001413 amino acids Chemical class 0.000 claims description 37
• 238000004519 manufacturing process Methods 0.000 claims description 18
• 206010033645 Pancreatitis Diseases 0.000 claims description 15
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
• 230000001575 pathological effect Effects 0.000 claims description 14
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 9
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 9
• 230000001404 mediated effect Effects 0.000 claims description 8
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 7
• 208000006673 asthma Diseases 0.000 claims description 7
• 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 6
• 208000031886 HIV Infections Diseases 0.000 claims description 6
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
• 201000003229 acute pancreatitis Diseases 0.000 claims description 5
• 235000015097 nutrients Nutrition 0.000 claims description 5
• 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 4
• 206010033647 Pancreatitis acute Diseases 0.000 claims description 4
• 239000001963 growth medium Substances 0.000 claims description 4
• 238000002955 isolation Methods 0.000 claims description 4
• 208000008423 pleurisy Diseases 0.000 claims description 4
• 206010039083 rhinitis Diseases 0.000 claims description 4
• 208000037357 HIV infectious disease Diseases 0.000 claims description 3
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
• 239000013589 supplement Substances 0.000 claims description 3
• 208000012902 Nervous system disease Diseases 0.000 claims description 2
• 208000025966 Neurological disease Diseases 0.000 claims description 2
• 239000002671 adjuvant Substances 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
• 108010024976 Asparaginase Proteins 0.000 description 478
• 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 464
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 177
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 131
• 108010003541 Platelet Activating Factor Proteins 0.000 description 130
• 239000011780 sodium chloride Substances 0.000 description 96
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 87
• 239000000047 product Substances 0.000 description 87
• 239000000872 buffer Substances 0.000 description 75
• 241000700159 Rattus Species 0.000 description 70
• 108090000623 proteins and genes Proteins 0.000 description 68
• 241001465754 Metazoa Species 0.000 description 56
• 102000004190 Enzymes Human genes 0.000 description 51
• 108090000790 Enzymes Proteins 0.000 description 51
• 229940088598 enzyme Drugs 0.000 description 51
• 108020004414 DNA Proteins 0.000 description 50
• 239000007983 Tris buffer Substances 0.000 description 49
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 49
• 102000004169 proteins and genes Human genes 0.000 description 48
• 210000001519 tissue Anatomy 0.000 description 48
• 239000002299 complementary DNA Substances 0.000 description 47
• 235000018102 proteins Nutrition 0.000 description 44
• 235000001014 amino acid Nutrition 0.000 description 42
• 241000588724 Escherichia coli Species 0.000 description 41
• 229920002684 Sepharose Polymers 0.000 description 41
• 206010030113 Oedema Diseases 0.000 description 40
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 38
• 229940024606 amino acid Drugs 0.000 description 37
• 238000010828 elution Methods 0.000 description 34
• 238000002474 experimental method Methods 0.000 description 31
• 239000002773 nucleotide Substances 0.000 description 29
• 125000003729 nucleotide group Chemical group 0.000 description 29
• 238000000746 purification Methods 0.000 description 29
• 239000006228 supernatant Substances 0.000 description 29
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 26
• 239000013612 plasmid Substances 0.000 description 26
• 108010010737 Ceruletide Proteins 0.000 description 24
• 229930190815 caerulein Natural products 0.000 description 24
• YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 24
• 229960001706 ceruletide Drugs 0.000 description 24
• 210000004072 lung Anatomy 0.000 description 24
• YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 24
• 238000002347 injection Methods 0.000 description 23
• 239000007924 injection Substances 0.000 description 23
• 241000699670 Mus sp. Species 0.000 description 22
• 239000003446 ligand Substances 0.000 description 22
• 210000000496 pancreas Anatomy 0.000 description 22
• 210000002966 serum Anatomy 0.000 description 22
• 239000002609 medium Substances 0.000 description 21
• 241000699666 Mus <mouse, genus> Species 0.000 description 20
• 210000002683 foot Anatomy 0.000 description 20
• 239000001488 sodium phosphate Substances 0.000 description 20
• 229910000162 sodium phosphate Inorganic materials 0.000 description 20
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 20
• 102000007330 LDL Lipoproteins Human genes 0.000 description 19
• 108010007622 LDL Lipoproteins Proteins 0.000 description 19
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 19
• 239000001045 blue dye Substances 0.000 description 19
• 210000004556 brain Anatomy 0.000 description 19
• 238000001802 infusion Methods 0.000 description 19
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
• 238000010790 dilution Methods 0.000 description 18
• 239000012895 dilution Substances 0.000 description 18
• 238000009396 hybridization Methods 0.000 description 18
• 230000002829 reductive effect Effects 0.000 description 18
• 239000004382 Amylase Substances 0.000 description 17
• 102000013142 Amylases Human genes 0.000 description 17
• 108010065511 Amylases Proteins 0.000 description 17
• 235000019418 amylase Nutrition 0.000 description 17
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 17
• 239000000499 gel Substances 0.000 description 17
• 210000002540 macrophage Anatomy 0.000 description 17
• 239000000523 sample Substances 0.000 description 17
• 239000012528 membrane Substances 0.000 description 16
• 239000000203 mixture Substances 0.000 description 16
• 210000001616 monocyte Anatomy 0.000 description 16
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 16
• 229920000053 polysorbate 80 Polymers 0.000 description 16
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 15
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 15
• 102000004882 Lipase Human genes 0.000 description 15
• 108090001060 Lipase Proteins 0.000 description 15
• 239000004367 Lipase Substances 0.000 description 15
• 206010028851 Necrosis Diseases 0.000 description 15
• 239000013504 Triton X-100 Substances 0.000 description 15
• 229920004890 Triton X-100 Polymers 0.000 description 15
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 15
• 235000019421 lipase Nutrition 0.000 description 15
• 230000017074 necrotic cell death Effects 0.000 description 15
• 239000000758 substrate Substances 0.000 description 15
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
• 206010061218 Inflammation Diseases 0.000 description 14
• 238000005349 anion exchange Methods 0.000 description 14
• 238000005277 cation exchange chromatography Methods 0.000 description 14
• 230000001965 increasing effect Effects 0.000 description 14
• 230000004054 inflammatory process Effects 0.000 description 14
• 210000004379 membrane Anatomy 0.000 description 14
• 239000002953 phosphate buffered saline Substances 0.000 description 14
• 150000003839 salts Chemical class 0.000 description 14
• 238000012163 sequencing technique Methods 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• 102000003896 Myeloperoxidases Human genes 0.000 description 13
• 108090000235 Myeloperoxidases Proteins 0.000 description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 description 13
• 238000004458 analytical method Methods 0.000 description 13
• 238000005341 cation exchange Methods 0.000 description 13
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
• 108020004705 Codon Proteins 0.000 description 12
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• 210000004369 blood Anatomy 0.000 description 12
• 239000008280 blood Substances 0.000 description 12
• 238000005119 centrifugation Methods 0.000 description 12
• 230000006378 damage Effects 0.000 description 12
• 239000006167 equilibration buffer Substances 0.000 description 12
• HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 230000000968 intestinal effect Effects 0.000 description 12
• 239000002245 particle Substances 0.000 description 12
• 229920001993 poloxamer 188 Polymers 0.000 description 12
• 210000000278 spinal cord Anatomy 0.000 description 12
• 241000700198 Cavia Species 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 230000002255 enzymatic effect Effects 0.000 description 11
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 11
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 11
• 230000009467 reduction Effects 0.000 description 11
• 210000003462 vein Anatomy 0.000 description 11
• 238000005406 washing Methods 0.000 description 11
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 210000004899 c-terminal region Anatomy 0.000 description 10
• 238000004587 chromatography analysis Methods 0.000 description 10
• 230000000875 corresponding effect Effects 0.000 description 10
• 230000004927 fusion Effects 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 210000002569 neuron Anatomy 0.000 description 10
• 239000008188 pellet Substances 0.000 description 10
• 150000003904 phospholipids Chemical class 0.000 description 10
• 238000013519 translation Methods 0.000 description 10
• 241000283690 Bos taurus Species 0.000 description 9
• 108700024394 Exon Proteins 0.000 description 9
• 108010058846 Ovalbumin Proteins 0.000 description 9
• 229920000392 Zymosan Polymers 0.000 description 9
• 239000005557 antagonist Substances 0.000 description 9
• 230000003197 catalytic effect Effects 0.000 description 9
• 238000010367 cloning Methods 0.000 description 9
• 239000003636 conditioned culture medium Substances 0.000 description 9
• 230000001086 cytosolic effect Effects 0.000 description 9
• 210000003979 eosinophil Anatomy 0.000 description 9
• 239000013604 expression vector Substances 0.000 description 9
• WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
• 239000008103 glucose Substances 0.000 description 9
• 230000003834 intracellular effect Effects 0.000 description 9
• 238000007912 intraperitoneal administration Methods 0.000 description 9
• 210000000440 neutrophil Anatomy 0.000 description 9
• 229940092253 ovalbumin Drugs 0.000 description 9
• 230000002685 pulmonary effect Effects 0.000 description 9
• 210000000813 small intestine Anatomy 0.000 description 9
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
• 206010029350 Neurotoxicity Diseases 0.000 description 8
• 206010044221 Toxic encephalopathy Diseases 0.000 description 8
• 238000009825 accumulation Methods 0.000 description 8
• 230000005779 cell damage Effects 0.000 description 8
• 208000037887 cell injury Diseases 0.000 description 8
• 210000001638 cerebellum Anatomy 0.000 description 8
• MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 8
• 238000007865 diluting Methods 0.000 description 8
• 229960005051 fluostigmine Drugs 0.000 description 8
• 210000004408 hybridoma Anatomy 0.000 description 8
• 230000007062 hydrolysis Effects 0.000 description 8
• 238000006460 hydrolysis reaction Methods 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 231100000228 neurotoxicity Toxicity 0.000 description 8
• 230000007135 neurotoxicity Effects 0.000 description 8
• 239000000902 placebo Substances 0.000 description 8
• 229940068196 placebo Drugs 0.000 description 8
• 210000000952 spleen Anatomy 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 210000003437 trachea Anatomy 0.000 description 8
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
• 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
• 238000000636 Northern blotting Methods 0.000 description 7
• 239000002033 PVDF binder Substances 0.000 description 7
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000015556 catabolic process Effects 0.000 description 7
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 230000008595 infiltration Effects 0.000 description 7
• 238000001764 infiltration Methods 0.000 description 7
• 210000000936 intestine Anatomy 0.000 description 7
• 239000012139 lysis buffer Substances 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 108020004999 messenger RNA Proteins 0.000 description 7
• -1 octadecyl silica gel Chemical compound 0.000 description 7
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 7
• 230000010076 replication Effects 0.000 description 7
• 210000001541 thymus gland Anatomy 0.000 description 7
• 238000001890 transfection Methods 0.000 description 7
• 230000002792 vascular Effects 0.000 description 7
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 101100296165 Mus musculus Pafah2 gene Proteins 0.000 description 6
• 108010076504 Protein Sorting Signals Proteins 0.000 description 6
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
• 102000004142 Trypsin Human genes 0.000 description 6
• 108090000631 Trypsin Proteins 0.000 description 6
• 239000000443 aerosol Substances 0.000 description 6
• 229940098773 bovine serum albumin Drugs 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 210000001072 colon Anatomy 0.000 description 6
• 235000018417 cysteine Nutrition 0.000 description 6
• 238000006731 degradation reaction Methods 0.000 description 6
• 230000004069 differentiation Effects 0.000 description 6
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
• 239000012530 fluid Substances 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 238000010562 histological examination Methods 0.000 description 6
• 229930182817 methionine Natural products 0.000 description 6
• 230000035699 permeability Effects 0.000 description 6
• 229920002401 polyacrylamide Polymers 0.000 description 6
• 238000011552 rat model Methods 0.000 description 6
• 238000003259 recombinant expression Methods 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 239000008399 tap water Substances 0.000 description 6
• 235000020679 tap water Nutrition 0.000 description 6
• 239000012588 trypsin Substances 0.000 description 6
• 102000004895 Lipoproteins Human genes 0.000 description 5
• 108090001030 Lipoproteins Proteins 0.000 description 5
• 208000004852 Lung Injury Diseases 0.000 description 5
• 241001460678 Napo <wasp> Species 0.000 description 5
• 206010030124 Oedema peripheral Diseases 0.000 description 5
• 229920001213 Polysorbate 20 Polymers 0.000 description 5
• 239000012614 Q-Sepharose Substances 0.000 description 5
• 206010069363 Traumatic lung injury Diseases 0.000 description 5
• 238000002835 absorbance Methods 0.000 description 5
• 235000003704 aspartic acid Nutrition 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
• 229910052799 carbon Inorganic materials 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 230000009089 cytolysis Effects 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
• 239000002158 endotoxin Substances 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 239000012537 formulation buffer Substances 0.000 description 5
• 238000007901 in situ hybridization Methods 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 238000010253 intravenous injection Methods 0.000 description 5
• 231100000515 lung injury Toxicity 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 210000002741 palatine tonsil Anatomy 0.000 description 5
• 210000000277 pancreatic duct Anatomy 0.000 description 5
• 230000036470 plasma concentration Effects 0.000 description 5
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
• 239000001509 sodium citrate Substances 0.000 description 5
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
• 238000001228 spectrum Methods 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 241000701832 Enterobacteria phage T3 Species 0.000 description 4
• 241000287828 Gallus gallus Species 0.000 description 4
• 208000032843 Hemorrhage Diseases 0.000 description 4
• 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 4
• 101001064282 Homo sapiens Platelet-activating factor acetylhydrolase IB subunit beta Proteins 0.000 description 4
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
• SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 4
• 239000000020 Nitrocellulose Substances 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
• 108700023400 Platelet-activating factor receptors Proteins 0.000 description 4
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
• 239000004098 Tetracycline Substances 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 235000004279 alanine Nutrition 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 125000000539 amino acid group Chemical group 0.000 description 4
• 238000000540 analysis of variance Methods 0.000 description 4
• 108091008324 binding proteins Proteins 0.000 description 4
• 210000000133 brain stem Anatomy 0.000 description 4
• 210000005013 brain tissue Anatomy 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 210000002257 embryonic structure Anatomy 0.000 description 4
• 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 231100000516 lung damage Toxicity 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 210000004400 mucous membrane Anatomy 0.000 description 4
• 229920001220 nitrocellulos Polymers 0.000 description 4
• 102000030769 platelet activating factor receptor Human genes 0.000 description 4
• 229910000160 potassium phosphate Inorganic materials 0.000 description 4
• 235000011009 potassium phosphates Nutrition 0.000 description 4
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000037452 priming Effects 0.000 description 4
• 230000001681 protective effect Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 230000009919 sequestration Effects 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 229960002180 tetracycline Drugs 0.000 description 4
• 229930101283 tetracycline Natural products 0.000 description 4
• 235000019364 tetracycline Nutrition 0.000 description 4
• 150000003522 tetracyclines Chemical class 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 241000251468 Actinopterygii Species 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 229920001917 Ficoll Polymers 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 241000282553 Macaca Species 0.000 description 3
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 241000009328 Perro Species 0.000 description 3
• 206010037423 Pulmonary oedema Diseases 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• 108020005038 Terminator Codon Proteins 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 208000038016 acute inflammation Diseases 0.000 description 3
• 230000006022 acute inflammation Effects 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 229960004538 alprazolam Drugs 0.000 description 3
• 229960000723 ampicillin Drugs 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 210000000702 aorta abdominal Anatomy 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 210000003710 cerebral cortex Anatomy 0.000 description 3
• 230000003196 chaotropic effect Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 150000001945 cysteines Chemical class 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 238000000855 fermentation Methods 0.000 description 3
• 230000004151 fermentation Effects 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 230000001605 fetal effect Effects 0.000 description 3
• 235000019688 fish Nutrition 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 238000001641 gel filtration chromatography Methods 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 210000004884 grey matter Anatomy 0.000 description 3
• 238000011554 guinea pig model Methods 0.000 description 3
• 210000000548 hind-foot Anatomy 0.000 description 3
• 230000000971 hippocampal effect Effects 0.000 description 3
• 210000001320 hippocampus Anatomy 0.000 description 3
• 230000036732 histological change Effects 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 208000033849 hyperamylasemia Diseases 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 239000007928 intraperitoneal injection Substances 0.000 description 3
• 230000000302 ischemic effect Effects 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000001926 lymphatic effect Effects 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 210000004980 monocyte derived macrophage Anatomy 0.000 description 3
• 238000013425 morphometry Methods 0.000 description 3
• 210000004877 mucosa Anatomy 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 230000002887 neurotoxic effect Effects 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000002028 premature Effects 0.000 description 3
• 230000000770 proinflammatory effect Effects 0.000 description 3
• 210000001147 pulmonary artery Anatomy 0.000 description 3
• 208000005333 pulmonary edema Diseases 0.000 description 3
• 239000013014 purified material Substances 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000012064 sodium phosphate buffer Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000005030 transcription termination Effects 0.000 description 3
• 230000014621 translational initiation Effects 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
• 108020005029 5' Flanking Region Proteins 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 206010003497 Asphyxia Diseases 0.000 description 2
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
• 241000972773 Aulopiformes Species 0.000 description 2
• COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 229920002271 DEAE-Sepharose Polymers 0.000 description 2
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 241000289427 Didelphidae Species 0.000 description 2
• 108010037352 FITC-albumin Proteins 0.000 description 2
• 206010017982 Gastrointestinal necrosis Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 101800001509 Large capsid protein Proteins 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 208000036364 Normal newborn Diseases 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 101150003085 Pdcl gene Proteins 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
• 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
• 102000003992 Peroxidases Human genes 0.000 description 2
• 102100026918 Phospholipase A2 Human genes 0.000 description 2
• 101710096328 Phospholipase A2 Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• IOUUIFSIQMVYKP-UHFFFAOYSA-N Tetradecyl acetate Chemical compound CCCCCCCCCCCCCCOC(C)=O IOUUIFSIQMVYKP-UHFFFAOYSA-N 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 229960005054 acepromazine Drugs 0.000 description 2
• NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 230000009285 allergic inflammation Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 238000005571 anion exchange chromatography Methods 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000000621 bronchi Anatomy 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 210000005056 cell body Anatomy 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 239000013522 chelant Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000011210 chromatographic step Methods 0.000 description 2
• 239000012501 chromatography medium Substances 0.000 description 2
• 210000001953 common bile duct Anatomy 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 210000003618 cortical neuron Anatomy 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 229960002086 dextran Drugs 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• 239000013024 dilution buffer Substances 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 229960003699 evans blue Drugs 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 239000008098 formaldehyde solution Substances 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 210000000232 gallbladder Anatomy 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 239000003862 glucocorticoid Substances 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 210000004565 granule cell Anatomy 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 210000004276 hyalin Anatomy 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000002991 immunohistochemical analysis Methods 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 230000000415 inactivating effect Effects 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
• 210000004731 jugular vein Anatomy 0.000 description 2
• 229940015418 ketaset Drugs 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 208000018773 low birth weight Diseases 0.000 description 2
• 231100000533 low birth weight Toxicity 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 210000000274 microglia Anatomy 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 231100000189 neurotoxic Toxicity 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 229960001412 pentobarbital Drugs 0.000 description 2
• 229960002275 pentobarbital sodium Drugs 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 210000001986 peyer's patch Anatomy 0.000 description 2
• 210000003800 pharynx Anatomy 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 210000002826 placenta Anatomy 0.000 description 2
• 238000011176 pooling Methods 0.000 description 2
• 239000008057 potassium phosphate buffer Substances 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 239000012264 purified product Substances 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000011555 rabbit model Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 229940069575 rompun Drugs 0.000 description 2
• 235000019515 salmon Nutrition 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000004088 simulation Methods 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 239000011573 trace mineral Substances 0.000 description 2
• 235000013619 trace mineral Nutrition 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000029534 trypsinogen activation Effects 0.000 description 2
• 238000013042 tunel staining Methods 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 230000008728 vascular permeability Effects 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 238000005303 weighing Methods 0.000 description 2
• 239000002023 wood Substances 0.000 description 2
• QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
• SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 101710126783 Acetyl-hydrolase Proteins 0.000 description 1
• 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
• 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 241001156002 Anthonomus pomorum Species 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 206010053555 Arthritis bacterial Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 239000012619 Butyl Sepharose® Substances 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 108091033380 Coding strand Proteins 0.000 description 1
• 108700010070 Codon Usage Proteins 0.000 description 1
• 206010011703 Cyanosis Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010051392 Diapedesis Diseases 0.000 description 1
• 241000289422 Didelphis virginiana Species 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 102400000686 Endothelin-1 Human genes 0.000 description 1
• 101800004490 Endothelin-1 Proteins 0.000 description 1
• 241001288713 Escherichia coli MC1061 Species 0.000 description 1
• 229940122601 Esterase inhibitor Drugs 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 206010015719 Exsanguination Diseases 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 241000713889 Friend spleen focus-forming virus Species 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000015779 HDL Lipoproteins Human genes 0.000 description 1
• 108010010234 HDL Lipoproteins Proteins 0.000 description 1
• 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• 206010067725 Hyperlipasaemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 208000004575 Infectious Arthritis Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OKIBNKKYNPBDRS-UHFFFAOYSA-N Mefluidide Chemical compound CC(=O)NC1=CC(NS(=O)(=O)C(F)(F)F)=C(C)C=C1C OKIBNKKYNPBDRS-UHFFFAOYSA-N 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
• 229920002274 Nalgene Polymers 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 206010033654 Pancreatitis necrotising Diseases 0.000 description 1
• 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
• 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 241000577979 Peromyscus spicilegus Species 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 241000566598 Podomys floridanus Species 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
• 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
• 206010036600 Premature labour Diseases 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010070774 Respiratory tract oedema Diseases 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 206010061372 Streptococcal infection Diseases 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 102000002933 Thioredoxin Human genes 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 102000018690 Trypsinogen Human genes 0.000 description 1
• 108010027252 Trypsinogen Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 210000001552 airway epithelial cell Anatomy 0.000 description 1
• PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 238000011316 allogeneic transplantation Methods 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 108700003859 araC Genes Proteins 0.000 description 1
• 101150044616 araC gene Proteins 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 210000002565 arteriole Anatomy 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 238000007846 asymmetric PCR Methods 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 210000001084 basket cell Anatomy 0.000 description 1
• 238000010923 batch production Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• VVAVKBBTPWYADW-RVTJCSDESA-L biebrich scarlet Chemical compound [Na+].[Na+].OC1=CC=C2C=CC=CC2=C1\N=N\C(C(=C1)S([O-])(=O)=O)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 VVAVKBBTPWYADW-RVTJCSDESA-L 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 238000009640 blood culture Methods 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 210000003123 bronchiole Anatomy 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 229960003669 carbenicillin Drugs 0.000 description 1
• FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 210000001159 caudate nucleus Anatomy 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 210000003591 cerebellar nuclei Anatomy 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 210000001100 crypt cell Anatomy 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 238000011833 dog model Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000003241 endoproteolytic effect Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 239000002329 esterase inhibitor Substances 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 238000013290 female long evans rat Methods 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 210000004055 fourth ventricle Anatomy 0.000 description 1
• 210000001652 frontal lobe Anatomy 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 238000010448 genetic screening Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 210000001280 germinal center Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 108010026195 glycanase Proteins 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 239000012510 hollow fiber Substances 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000003960 inflammatory cascade Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000009413 insulation Methods 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 238000002093 isoelectric focusing polyacrylamide gel electrophoresis Methods 0.000 description 1
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 235000020061 kirsch Nutrition 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
• 229910052808 lithium carbonate Inorganic materials 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 150000004668 long chain fatty acids Chemical class 0.000 description 1
• 230000027928 long-term synaptic potentiation Effects 0.000 description 1
• 210000004705 lumbosacral region Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000001055 magnesium Nutrition 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
• 210000003622 mature neutrocyte Anatomy 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 210000001363 mesenteric artery superior Anatomy 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 238000007491 morphometric analysis Methods 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000007372 neural signaling Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 210000000869 occipital lobe Anatomy 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 238000007248 oxidative elimination reaction Methods 0.000 description 1
• 239000006174 pH buffer Substances 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 238000007427 paired t-test Methods 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000032696 parturition Effects 0.000 description 1
• 230000004963 pathophysiological condition Effects 0.000 description 1
• 108010006260 pegylated granulocyte colony-stimulating factor Proteins 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 238000012510 peptide mapping method Methods 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 238000001558 permutation test Methods 0.000 description 1
• QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
• 239000002644 phorbol ester Substances 0.000 description 1
• 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 210000004910 pleural fluid Anatomy 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000000270 postfertilization Effects 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 208000026440 premature labor Diseases 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 210000003456 pulmonary alveoli Anatomy 0.000 description 1
• 239000012521 purified sample Substances 0.000 description 1
• 210000000449 purkinje cell Anatomy 0.000 description 1
• 210000002637 putamen Anatomy 0.000 description 1
• 229940076788 pyruvate Drugs 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 238000011867 re-evaluation Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 210000001202 rhombencephalon Anatomy 0.000 description 1
• 239000007320 rich medium Substances 0.000 description 1
• 238000010079 rubber tapping Methods 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000003118 sandwich ELISA Methods 0.000 description 1
• 230000000580 secretagogue effect Effects 0.000 description 1
• 230000018448 secretion by cell Effects 0.000 description 1
• 229940082569 selenite Drugs 0.000 description 1
• MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 201000001223 septic arthritis Diseases 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 108020002447 serine esterase Proteins 0.000 description 1
• 102000005428 serine esterase Human genes 0.000 description 1
• 210000002151 serous membrane Anatomy 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 108010079522 solysime Proteins 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 201000005789 splenic abscess Diseases 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 210000001587 telencephalon Anatomy 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 210000003478 temporal lobe Anatomy 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
• 210000001103 thalamus Anatomy 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 231100000816 toxic dose Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 125000002987 valine group Chemical class [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000001631 vena cava inferior Anatomy 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1